July 14 (Reuters) - The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the regulator said on Tuesday, making it the company's first product to gain market entry and ...

REVTORPYK (gedatolisib) vial and box REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K ...

Celcuity said Revtorpyk is the first drug of its kind to receive FDA approval. "The PI3K/AKT/mTOR, or PAM, pathway is one of the most important targets in cancer, but comprehensiv ...

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...

Approval addresses the ~60% of HR+/HER2− advanced cases with PIK3CA wild-type disease who are ineligible for PI3Kα-selective inhibitors. VIKTORIA-1 met co-primary PFS end points with gedatolisib ...

Possible benefits of vitamin B6 include improved mood and memory, and reduced nausea during pregnancy. Older research has shown possible benefits for premenstrual syndrome and reduced risk of heart ...

2 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, ...

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal ...